TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Hudson Biotech · Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction
Phase 1 / Phase 2
Recruiting
80
2026-03
Industry sponsor intelligence
Hudson BiotechClinical Pipeline.
Lead-sponsor view of Hudson Biotech's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 4
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 155
Pipeline overview
Programs by phase and activity.
Velocity
Hudson Biotech trials by start year
Study start year · indexed snapshot
Development
Trials by phase
5phase labels
Early Phase 10
Phase 11
Phase 24
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| BPC-157 → | 1 | 0 | 1 | 0 | 0 | 1 |
| Retatrutide → | 1 | 0 | 1 | 0 | 0 | 1 |
| Tesamorelin → | 1 | 0 | 1 | 0 | 0 | 1 |
| Thymosin Beta-4 → | 1 | 1 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Hudson Biotech · Metabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis
Phase 2
Recruiting
120
2026-03
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech · Obesity
Phase 2
Recruiting
300
2026-03
BPC 157 for Acute Hamstring Muscle Strain Repair
Hudson Biotech · Hamstring Muscle Strain · Skeletal Muscle Injury
Phase 2
Recruiting
120
2026-02
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Hudson Biotech studies.
This page groups studies where Hudson Biotech is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07487363TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDMar 23, 2026NCT07481734Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)Mar 19, 2026NCT07467447Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightMar 12, 2026NCT07437547BPC 157 for Acute Hamstring Muscle Strain RepairFeb 27, 2026